Lepton Global Solutions Announces Partnership with Satcube to Expand its Network Offering for Small, Portable VSATs
9.3.2021 17:00:00 EET | Business Wire | Press release
Lepton Global Solutions (www.leptonglobal.com), a Kymeta company, and leading provider of satellite-based customized turn-key communications solutions and services, announced today a strategic partnership with Satcube (www.satcube.com). The partnership will add Satcube’s class of extremely small VSAT terminals to the company’s global satellite network, which is engineered to support terminal aperture sizes down to 45cm. In turn, Lepton Global Solutions will offer Satcube Ku terminals globally as a comms-on-the-pause (COTP) solution that are complementary with the Kymeta™ u8 comms-on-the-move (COTM) offering, running both on the same frequencies with easily transportable and operated hardware.
Together, Lepton Global Solutions and Satcube are challenging the traditional ways satellite communications are delivered and consumed through highly automated, easily transportable products low in size, weight, and power. The goal of the partnership is to deliver world-class technology and services to defense, public safety, and commercial customers globally. Both the Satcube and the u8 terminal are designed to fulfill tactical, easy-to-use operational requirements. Their differing form factors and capability sets address differing applications of users on the move.
“Most commercial satellite service networks are designed for larger aperture antennas that operate at broadside, which means that smaller, flat panel terminals like the Satcube and u8 are not globally supported,” said Isabel LeBoutillier, Vice President of Kymeta Connect and Government Programs. “Our network has been built from the ground up to accommodate the technical requirements of this newer class of extremely small, flat-panel VSAT terminals. The partnership with Satcube will allow us to deliver superior connectivity options for more applications to our mobile customers.”
“This partnership will allow our companies to better meet the requirements of our complementary customers and provide solutions that fit the needs of a broader audience,” said Jakob Kallmer, Satcube CEO and founder. “Our relationship with Lepton will enable Satcube to provide a more seamless and reliable connectivity experience to our customers globally, and we couldn’t be more thrilled to be working together.”
Satcube Ku is an all-in-one compact carry-on satellite terminal with a flat antenna the size of a large laptop. The terminal enables users to create an easy-to-use Wi-Fi hotspot and receive high-speed broadband connection in less than one minute to execute critical, on the spot work assignments and communications.
Lepton Global Solutions and Satcube leverage Kymeta Broadband, which is the first satellite service designed to serve the unique characteristics of flat panel antennas used in land-mobile applications. Built from the ground up and software defined for disadvantaged terminals and antennas, the service ensures that customers stay connected without latency or throughput challenges. Customers receive capacity through a managed network that aggregates multiple satellite providers and hundreds of operators for global coverage.
Lepton’s network offering for these terminals includes global customized CIR plans as well as Kymeta Broadband’s satellite 5x2 MIR and hybrid satellite-cellular options. Service may be purchased for individual terminals or shared among multiple terminals.
About Lepton Global Solutions:
Lepton Global Solutions, a Kymeta company, specializes in the engineering and delivery of customized, yet cost-effective, turnkey satellite communications solutions to commercial and government customers. Lepton’s end-to-end solutions, which go beyond managed satellite services to include VSAT equipment installation, 24×7 technical support and customized back end IT infrastructure, are tailored to meet customer-specific needs.
Lepton is headquartered outside of Washington, D.C. in Tysons Corner, Virginia.
For additional information, please visit www.leptonglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005025/en/
Contact information
Business Inquiries for Lepton Global Solutions:
Jon Maron
Vice President of Marketing and Communications
Lepton Global Solutions
+1 425.658.8827
jmaron@kymetacorp.com
Media Inquiries for Lepton Global Solutions:
Amanda Barry
Associated Director PR
The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom